| Literature DB >> 21357795 |
Tanja C Adam1, Rebecca E Hasson, Christianne J Lane, Jaimie N Davis, Marc J Weigensberg, Donna Spruijt-Metz, Michael I Goran.
Abstract
OBJECTIVE: To examine the relationship of fasting indicators of insulin sensitivity with a more invasive measure of insulin sensitivity (frequently sampled intravenous glucose tolerance test [FSIVGTT]) and the effect of Tanner stage and ethnicity on that relationship. RESEARCH DESIGN AND METHODS: Data were analyzed from 149 overweight girls (97 Hispanic and 52 African American) who were either in the early stages of maturation defined by Tanner stages 1 or 2 (52 Hispanic and 18 African American) or in the later stages of maturation defined by Tanner stages 4 and 5 (45 Hispanic and 34 African American). Fasting indicators of insulin sensitivity (IS) included fasting insulin and glucose and the homeostasis model assessment of insulin resistance (HOMA-IR). IS was derived from an FSIVGTT with minimal modeling.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21357795 PMCID: PMC3064063 DOI: 10.2337/dc10-1593
Source DB: PubMed Journal: Diabetes Care ISSN: 0149-5992 Impact factor: 19.112
Participants’ characteristics separated by Tanner stage
| Tanner stages 1 and 2 | Tanner stages 4 and 5 | |||||
|---|---|---|---|---|---|---|
| African American | Hispanic | African American | Hispanic | |||
| 18 | 52 | 34 | 45 | |||
| Age (years) | 8.9 ± 0.8 | 9.4 ± 1.6 | 0.13 | 15.4 ± 1 | 15.3 ± 1 | 0.55 |
| Height (cm) | 141.6 ± 5.9 | 137.1 ± 11.1 | 0.08 | 165.4 ± 7.8 | 158.9 ± 15.4 | 0.02 |
| Weight (kg) | 46.0 ± 11.6 | 41.3 ± 12.7 | 0.13 | 98.9.±23.5 | 86.5 ± 18.5 | 0.01 |
| BMI (kg/m2) | 22.9 ± 5.1 | 25.1 ± 4.2 | 0.11 | 36.1 ± 8 | 33.8 ± 6.9 | 0.19 |
| Fat mass (kg) | 14.6 ± 6.6 | 15.6 ± 8.3 | 0.59 | 35.9 ± 12.4 | 35.7 ± 10.9 | 0.93 |
| FFM (kg) | 33.02 ± 6.0 | 28.9 ± 8.0 | 0.05 | 54.6.±7.9 | 48.8 ± 8 | 0.00 |
| SAT (L) | 3.7 ± 3.2 | 4.3 ± 2.8 | 0.45 | 15.5 ± 26.8 | 9.8 ± 3.5 | 0.00 |
| VAT (L) | 0.35 ± 0.33 | 0.73 ± 0.60 | 0.02 | 1.2 ± 0.8 | 1.3 ± 0.8 | 0.35 |
| HFF (%) | 4.1 ± 1.8 | 6.5 ± 6.7 | 0.17 | 3.9 ± 1.9 | 6.5 ± 6.2 | 0.02 |
| Fasting insulin (μU/mL) | 11.9 ± 9.9 | 13.6 ± 10.8 | 0.54 | 20.7 ± 10.1 | 21.3 ± 11.9 | 0.79 |
| Fasting glucose (mg/L) | 87.5 ± 6.7 | 92.6 ± 5.4 | 0.00 | 87.9 ± 6.4 | 91.5 ± 5.5 | 0.01 |
| IS [(× 10−4/min−1)/(μU/mL)] | 3.0 ± 1.8 | 3.3 ± 1.8 | 0.59 | 1.3 ± 0.8 | 1.6 ± 0.8 | 0.10 |
| DI (× min−1) | 3650 ± 2024 | 2678 ± 1148 | 0.01 | 2230 ± 1456 | 1633 ± 745 | 0.02 |
| HOMA-IR | 2.7 ± 2.3 | 3.1 ± 2.6 | 0.50 | 4.5 ± 2.4 | 4.8 ± 2.7 | 0.65 |
SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue.
Figure 1Relationship of fasting insulin (A) and HOMA (B) with IS in Tanner stages 1 and 2.
Figure 2Relationship of fasting insulin (A) and HOMA (B) with IS in Tanner stages 4 and 5.